Literature DB >> 23646826

Efficacy and ligand bias at the μ-opioid receptor.

E Kelly1.   

Abstract

In order to describe drug action at a GPCR, a full understanding of the pharmacological terms affinity, efficacy and potency is necessary. This is true whether comparing the ability of different agonists to produce a measurable response in a cell or tissue, or determining the relative ability of an agonist to activate a single receptor subtype and produce multiple responses. There is a great deal of interest in the μ-opioid receptor (MOP receptor) and the ligands that act at this GPCR not only because of the clinically important analgesic effects produced by MOP agonists but also because of their liability to induce adverse effects such as respiratory depression and dependence. Our understanding of the mechanisms underlying these effects, as well as the ability to develop new, more effective MOP receptor drugs, depends upon the accurate determination of the efficacy with which these ligands induce coupling of MOP receptors to downstream signalling events. In this review, which is written with the minimum of mathematical content, the basic meaning of terms including efficacy, intrinsic activity and intrinsic efficacy is discussed, along with their relevance to the field of MOP receptor pharmacology, and in particular in relation to biased agonism at this important GPCR.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  GPCR; efficacy; intrinsic efficacy; ligand bias; μ-opioid receptor

Mesh:

Substances:

Year:  2013        PMID: 23646826      PMCID: PMC3724102          DOI: 10.1111/bph.12222

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  98 in total

Review 1.  Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Authors:  P G Strange
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

2.  Use of functional assays to detect and quantify functional selectivity.

Authors: 
Journal:  Drug Discov Today Technol       Date:  2010

3.  Endomorphin-stimulated [35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors.

Authors:  L J Sim; Q Liu; S R Childers; D E Selley
Journal:  J Neurochem       Date:  1998-04       Impact factor: 5.372

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Opiate receptors in the rat vas deferens.

Authors:  C F Smith; M J Rance
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

6.  Morphine-like opiates selectively antagonize receptor-arrestin interactions.

Authors:  Paola Molinari; Vanessa Vezzi; Maria Sbraccia; Cristina Grò; Daniela Riitano; Caterina Ambrosio; Ida Casella; Tommaso Costa
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

7.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.

Authors:  E H Cox; T Kerbusch; P H Van der Graaf; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1998-03       Impact factor: 4.030

8.  Evidence that behavioral phenotypes of morphine in β-arr2-/- mice are due to the unmasking of JNK signaling.

Authors:  Nitish Mittal; Miao Tan; Onyemachi Egbuta; Nina Desai; Cynthia Crawford; Cui-Wei Xie; Christopher Evans; Wendy Walwyn
Journal:  Neuropsychopharmacology       Date:  2012-04-11       Impact factor: 7.853

9.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more
  41 in total

1.  Effects of human SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of acetaminophen and opioid drugs by the cytosolic sulfotransferase SULT1A3.

Authors:  Ahsan F Bairam; Mohammed I Rasool; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Arch Biochem Biophys       Date:  2018-04-26       Impact factor: 4.013

Review 2.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

3.  The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist.

Authors:  M Alexander Stanczyk; Kathryn E Livingston; Louise Chang; Zara Y Weinberg; Manojkumar A Puthenveedu; John R Traynor
Journal:  Br J Pharmacol       Date:  2019-04-14       Impact factor: 8.739

Review 4.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 6.  Opiate pharmacology and relief of pain.

Authors:  Gavril W Pasternak
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

7.  Differential Desensitization Observed at Multiple Effectors of Somatic μ-Opioid Receptors Underlies Sustained Agonist-Mediated Inhibition of Proopiomelanocortin Neuron Activity.

Authors:  Philip D Fox; Shane T Hentges
Journal:  J Neurosci       Date:  2017-08-07       Impact factor: 6.167

Review 8.  A cellular perspective of bias at G protein-coupled receptors.

Authors:  Thomas J Fernandez; Monica De Maria; Braden T Lobingier
Journal:  Protein Sci       Date:  2020-04-27       Impact factor: 6.725

9.  Molecular dynamics of fentanyl bound to μ-opioid receptor.

Authors:  Piotr F J Lipiński; Małgorzata Jarończyk; Jan Cz Dobrowolski; Joanna Sadlej
Journal:  J Mol Model       Date:  2019-05-03       Impact factor: 1.810

10.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.